Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsPhase3

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Sponsor: AstraZeneca

NCT ID: NCT05624450

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Tozorakimab (drug), Placebo (drug)
How long the study runs
Study runs about 59 months (dates as stated)
About the drug or intervention
Tozorakimab — drug: Single IV dose of tozorakimab on Day 1. · Placebo — drug: Single IV dose of matching placebo on Day 1.
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
3,527
Started
2022-12-13
Last checked
2026-09

Plain English Summary

What is this study?

  • • Testing a new treatment for viral lung infection and acute respiratory failure
  • • Phase3 - 3,527 participants
  • • The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with viral lung infection and acute respiratory failure

Where?

  • • Bristol - Research Site
  • • Dundee - Research Site
  • • Glasgow - Research Site
  • • Glasgow - Research Site
  • • +11 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Viral Lung Infection and Acute Respiratory Failure

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓Adult participants ≥ 18 years old at the time of signing the agreement to take part form.
  • ✓Patients hospitalised with viral lung infection.
  • ✓Hypoxaemia requiring treatment with supplemental O2.
  • ✓Hypoxaemia is defined as:
  • ✓SpO2 ≤ 90% OR

Who cannot take part

  • ✗Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
  • ✗Ongoing IMV/ECMO at randomisation.
See the full criteria
Inclusion Criteria: * Adult participants ≥ 18 years old at the time of signing the informed consent form. * Patients hospitalised with viral lung infection. * Hypoxaemia requiring treatment with supplemental O2. Hypoxaemia is defined as: SpO2 ≤ 90% OR SpO2 ≤ 92% AND one or both of the following: Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement. Use of accessory muscles of respiration or RR (respiratory rate) \> 22. \- Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen. Exclusion Criteria: * Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition. * Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology. * Ongoing IMV/ECMO at randomisation.

Where Is This Study? (15 UK sites)

Research Site

Bristol BS105NB, United Kingdom

Recruiting

Research Site

Dundee DD1 9SY, United Kingdom

Recruiting

Research Site

Glasgow G4 0SF, United Kingdom

COMPLETED

Research Site

Glasgow G51 4TF, United Kingdom

WITHDRAWN

Research Site

Hampshire SO16 6YD, United Kingdom

Recruiting

Research Site

Huddersfield HD3 3EA, United Kingdom

Recruiting

Research Site

Leeds LS9 7TF, United Kingdom

Recruiting

Research Site

Leicester LE3 9QP, United Kingdom

Recruiting

Research Site

London W1T 7HA, United Kingdom

Recruiting

Research Site

London W2 1NY, United Kingdom

Recruiting

Research Site

London W6 8RF, United Kingdom

WITHDRAWN

Research Site

Oxford OX3 9DU, United Kingdom

Recruiting

Research Site

Prescot L35 5DR, United Kingdom

Recruiting

Research Site

Tyne and Wear NE29 8NH, United Kingdom

Recruiting

Research Site

Wythenshawe M23 9LT, United Kingdom

WITHDRAWN

How to Get in Touch

AstraZeneca Clinical Study Information Center

Sponsor contact

CONTACT

1-877-240-9479 information.center@astrazeneca.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-09